Robert W. Baird Lowers Illumina (NASDAQ:ILMN) Price Target to $90.00

Illumina (NASDAQ:ILMN) had its price target cut by stock analysts at Robert W. Baird from $127.00 to $90.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the life sciences company’s stock. Robert W. Baird’s price objective points to a potential upside of 6.32% from the stock’s current price.

Several other research analysts have also recently issued reports on ILMN. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Piper Sandler boosted their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $130.00 to $100.00 in a report on Monday, February 10th. Finally, Canaccord Genuity Group reduced their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Trading Down 1.2 %

ILMN opened at $84.65 on Wednesday. Illumina has a 12 month low of $80.18 and a 12 month high of $156.66. The stock has a market capitalization of $13.41 billion, a price-to-earnings ratio of -11.02, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The business has a fifty day moving average price of $119.36 and a 200 day moving average price of $131.84.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

Large investors have recently modified their holdings of the business. Versant Capital Management Inc raised its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina during the 4th quarter worth approximately $32,000. Fourth Dimension Wealth LLC purchased a new position in shares of Illumina during the 4th quarter worth approximately $40,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the 4th quarter worth approximately $45,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.